
Dabigatran etexilate
CAS No. 211915-06-9
Dabigatran etexilate( BIBR-1048 )
Catalog No. M13373 CAS No. 211915-06-9
A prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 30 | In Stock |
![]() ![]() |
5MG | 47 | In Stock |
![]() ![]() |
10MG | 65 | In Stock |
![]() ![]() |
50MG | 80 | In Stock |
![]() ![]() |
100MG | 108 | In Stock |
![]() ![]() |
200MG | 158 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameDabigatran etexilate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM.
-
DescriptionA prodrug of BIBR-953, which is a potent nonpeptide thrombin inhibitor with Ki of 4.5 nM; 10-fold less potent for Trypsin and no activity against Factor Xa, Plasmin, tPA and activated protein C; exhibits strong and long-lasting anticoagulant effects ex vivo and strong oral activity in different animal species.Thrombosis Approved(In Vitro):Dabigatran etexilate (BIBR 1048; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after administration, respectively.Dabigatran etexilate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively.Dabigatran etexilate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey.
-
In Vitro——
-
In VivoDabigatran etexilate (BIBR 1048; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after administration, respectively. Dabigatran etexilate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively.Dabigatran etexilate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey. Animal Model:Male rats (280-350 g) and rhesus monkeys of either sex (3-8 kg)Dosage:10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys Administration:Oral Result:Had dose- and time-dependent anticoagulant effects.
-
SynonymsBIBR-1048
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThrombin
-
Research AreaCardiovascular Disease
-
IndicationThrombosis
Chemical Information
-
CAS Number211915-06-9
-
Formula Weight627.7332
-
Molecular FormulaC34H41N7O5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(OCC)CCN(C1=NC=CC=C1)C(C2=CC=C3N(C)C(CNC4=CC=C(/C(N)=N\C(OCCCCCC)=O)C=C4)=NC3=C2)=O
-
Chemical Nameb-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
Melagatran
Melagatran is an orally available, direct synthetic thrombin inhibitor that does not require endogenous cofactors other than thrombin and does not significantly interact with any other enzymes in the coagulation cascade or with the fibrinolytic enzymes.
-
Naroparcil
Naroparcil, an orally available thioglycoside analog of 4-methylumbelliferyl β-D-xyloside, showed antithrombotic effects in the Wessler sludge model of venous thrombosis (jugular vein).
-
Enoxaparin sodium
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI).